menu
    • menu
    [{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Helix Acquisition Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Oncology Therapeutics \/ Helix Acquisition Corp. II","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Helix Acquisition Corp. II"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Cormorant Asset Management"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-8520","moa":"GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBO-8520","moa":"GTP","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Oncology Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for BBO-8520

    Menu

    BBO-8520

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BridgeBio Oncology Therapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            BridgeBio Oncology Therapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Helix Acquisition Corp. II

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            BBOT, Helix Acquisition Announce Merger to Advance RAS and PI3Kα Therapies

                            Details : The combined company will focus on the acceleration of pipeline clinical development, which includes BBO-8520. It is being evaluated for the treatment of KRASG12C mutant non-small cell lung cancer.

                            Product Name : BBO-8520

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 28, 2025

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Helix Acquisition Corp. II

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BridgeBio Oncology Therapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            BridgeBio Oncology Therapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio Oncology Receives FDA Fast Track for BBO-8520 in NSCLC

                            Details : BBO-8520 is a first-in-class direct inhibitor of KRASG12C (ON). It is being evaluated for the treatment of KRASG12C mutant non-small cell lung cancer.

                            Product Name : BBO-8520

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio: First Patient Dosed in ONKORAS-101 Trial for KRASG12C NSCLC

                            Details : BBO-8520 is a first-in-class direct inhibitor of KRASG12C (ON). It is being evaluated for the treatment of KRASG12C mutant non-small cell lung cancer.

                            Product Name : BBO-8520

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 06, 2024

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBO-8520

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio Gets FDA Clearance for IND Application of BBO-8520, a KRASG12C Inhibitor

                            Details : BBO-8520 is a first-in-class direct inhibitor of KRASG12C (ON). It is being evaluated for the treatment of KRASG12C mutant non-small cell lung cancer.

                            Product Name : BBO-8520

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 01, 2024

                            Lead Product(s) : BBO-8520

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cormorant Asset Management

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            BridgeBio Launches BBOT with $200 Million to Advance Precision Oncology Pipeline

                            Details : The net proceeds will support the clinical advancement of BBO-8520, which is being evaluated in early-stage clinical trials with pembrolizumab for treating KRASG12C mutated non-small cell lung cancer.

                            Product Name : BBO-8520

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 05, 2024

                            Lead Product(s) : BBO-8520,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cormorant Asset Management

                            Deal Size : $200.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            BridgeBio Pharma

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBO-8520

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generati...

                            Details : BBO-8520 is the first-known small molecule that directly binds and inhibits KRASG12C in both its active (GTP bound) and inactive (GDP bound) conformations, leading to differentiated activity in cancer patients with KRASG12C driven disease.

                            Product Name : BBO-8520

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 17, 2022

                            Lead Product(s) : BBO-8520

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth